Table 2.
The correlation of oxytocin levels at baseline with clinical variables in KD patients.
| r | P-value | |
|---|---|---|
| Ketamine use variables | ||
| Total years of ketamine use | −0.209 | 0.110 |
| Average daily dose in past 30 days (g/day) | 0.081 | 0.532 |
| Maximum daily dose in past 30 days (g/day) | 0.023 | 0.861 |
| Using days in past 30 days (days) | 0.064 | 0.621 |
| VAS | −0.055 | 0.673 |
| SDS | −0.253 | 0.058 |
| BDI | −0.159 | 0.217 |
| BAI | –0.263 | 0.039 |
| CTQ-SF | 0.013 | 0.924 |
| Total scores | 0.013 | 0.924 |
| Number of trauma types | −0.025 | 0.848 |
BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; CTQ-SF, Childhood Trauma Questionnaire-short form; SDS, Severity of Dependence Scale; VAS, Visual Analog Scale for craving. Bold highlights statistically significant values (p < 0.05).